Disease-Modifying Therapies for Rare Neurological Disorders

Elixiria is developing next-generation, brain- and peripheral-nerve-penetrant PPARγ-based therapeutics for high-unmet-need neurological diseases.

Problem

Patients with selected high-unmet-need rare neurological diseases have no approved disease-modifying therapies. Current treatments provide only partial relief and do not address the underlying drivers of oxidative stress, mitochondrial dysfunction, and neuroinflammation, leaving patients with progressive, debilitating disease and no treatments targeting the root causes.

Solution

ELB00824 is a brain-penetrant, edema-sparing PPARγ agonist that targets oxidative stress, mitochondrial dysfunction, and neuroinflammation in selected rare neurological diseases. ELB00824 is protected by granted composition-of-matter patents.

Market

Patients with two selected orphan neurological diseases with no approved disease-modifying therapies and a combined ~$10.7 billion U.S. peak sales opportunity

Business model

Elixiria advances ELB00824 to clinical proof-of-concept and monetizes it through out-licensing to pharmaceutical partners for upfront payments, milestones, and royalties, while targeting an M&A or IPO exit after Phase 2 data in one selected rare disease .

Team

He earned his Ph.D. from the University of Texas MD Anderson Cancer Center, completed postdoctoral training at Columbia University, and conducted foundational research on oxidative stress and neuroprotection under Professor LoPachin at Albert Einstein College of Medicine. He brings prior experience from a global pharmaceutical company

Professor and Chair of Anesthesiology at the University of New Mexico, with 36 years of pain research experience, ~200 publications, and 10 U.S. patents. She oversees ELB00824’s efficacy studies and grant-funded research.

He brings 10 years of venture capital experience managing $1 billion in assets and holds an MBA from Zhejiang University. He plays a key role in guiding Elixiria’s financial strategy.

Get in touch